Study protocol for a randomised controlled trial: Treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP) by Mazarico, E. et al.
1Mazarico E, et al. BMJ Open 2018;8:e020501. doi:10.1136/bmjopen-2017-020501
Open access 
Study protocol for a randomised 
controlled trial: treatment of early 
intrauterine growth restriction with low 
molecular weight heparin (TRACIP)
Edurne Mazarico,1,2,3 Anna Peguero,4 Marta Camprubí,1 Carlota Rovira,5 
Maria Dolores Gomez Roig,1,2,3 Daniel Oros,3,6 Patricia Ibáñez-Burillo,6 
Jon Schoorlemmer,7 Narcís Masoller,4 Maria Dolors Tàssies,8 Francesc Figueras4
To cite: Mazarico E, 
Peguero A, Camprubí M, 
et al.  Study protocol for 
a randomised controlled 
trial: treatment of early 
intrauterine growth restriction 
with low molecular weight 
heparin (TRACIP). BMJ Open 
2018;8:e020501. doi:10.1136/
bmjopen-2017-020501
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
020501).
Received 7 November 2017
Revised 7 May 2018
Accepted 12 June 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Francesc Figueras;  
 FFIGUERA@ clinic. cat
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction The incidence of intrauterine growth 
restriction (IUGR) is estimated at about 3% of 
pregnancies, and it is associated with 30% of all 
perinatal mortality and severe morbidity with adverse 
neurodevelopmental and cardiovascular health 
consequences in adult life. Early onset IUGR represents 
20%–30% of all cases and is highly associated with 
severe placental insufficiency. The existing evidence 
suggests that low molecular weight heparin (LMWH) 
has effects beyond its antithrombotic action, improving 
placental microvessel structure and function of pregnant 
women with vascular obstetric complications by 
normalising proangiogenic and antiapoptotic protein 
levels, cytokines and inflammatory factors. The objective 
of our study is to demonstrate the effectiveness of 
LMWH in prolonging gestation in pregnancies with early-
onset IUGR.
Methods and analysis This is a multicentre, triple-
blind, parallel-arm randomised clinical trial. Singleton 
pregnancies qualifying for early (20–32 weeks at 
diagnosis) placental IUGR (according to Delphi criteria) 
will be randomised to subcutaneous treatment with 
bemiparin 3500 IU/0.2 mL/day or placebo from 
inclusion at diagnosis to the time of delivery. Analyses 
will be based on originally assigned groups (intention-
to-treat). The primary objective will be analysed 
by comparing gestational age and prolongation of 
pregnancy (days) in each group with Student’s t-tests 
for independent samples and by comparing Kaplan-
Maier survival curves (from inclusion to delivery, log-
rank test). A linear regression model for gestational 
age at birth will consider the following covariates: 
gestational age at inclusion (continuous) and pre-
eclampsia (binary).
Ethics and dissemination The study will be conducted 
in accordance with the principles of Good Clinical 
Practice. This study was approved by the Clinical 
Research Ethics Committee (CEIC) of Sant Joan de Déu 
Hospital, on 13 July 2017. The trial is registered in 
the public registry www. clinicaltrial. gov. according to 
Science Law 14/2011, and the results will be published 
in an open access journal.
trial registration number NCT03324139; Pre-results.
IntroduCtIon  
background
Placental insufficiency and intrauterine growth 
restriction
Intrauterine growth restriction (IUGR) is 
defined as a failure to achieve the endorsed 
growth potential secondary to placental insuf-
ficiency. Its incidence is estimated at about 
3% of pregnancies, and it is associated with 
30% of all perinatal mortality and severe 
morbidity,1 with adverse neurodevelopmental 
and cardiovascular health consequences in 
adult life.
Early onset IUGR represents 20%–30% of 
all IUGR1 and presents in association with 
early pre-eclampsia (PE) in up to 50% of 
cases.1 This type of IUGR is highly associated 
with severe placental insufficiency; subse-
quent chronic fetal hypoxia is the major 
contributor to poor perinatal outcomes.2
The key to successful placental implanta-
tion is controlled activation of the haemo-
static system which balances the process of 
trophoblastic invasion and protects against 
bleeding.3 In PE and early onset IUGR, 
this vascular remodelling does not exist 
or is incomplete2 which leads to placental 
hypoperfusion associated with endothelial 
cell dysfunction and subsequent coagula-
tion, fibrin deposition and uteroplacental 
strengths and limitations of this study
 ► This is a multicentre, triple-blinded, randomised trial 
with two parallel groups.
 ► The primary outcome (prolongation of pregnancy) is 
a surrogate of perinatal health.
 ► The sample size limits the analysis of secondary 
outcomes.
 ► Follow-up of the offspring is limited to the neonatal 
period.
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thrombosis with local implications in the case of IUGR 
and systemic implications in the case of PE.4 Pathological 
examination of the placenta shows uteroplacental throm-
bosis, infarctions and fibrin deposits.
The natural history of placental insufficiency decreases 
fetal well-being, with a progression to hypoxia and acidosis; 
in clinical practice, this deterioration is monitored by 
Doppler study of the umbilical artery (which reflects the 
placental lesion) and ductus venosus (which reflects fetal 
cardiac diastolic failure secondary to acidosis) to individ-
ually time the delivery in an elective and adapted manner. 
The latency time to severe fetal deterioration is variable 
but is usually 3–4 weeks.5 It is estimated that between 24 
and 28 weeks, each week of prolonged gestation increases 
survival without sequelae by 10%–15%; and between 28 
and 32 weeks, it increases by 5%.6 The objective of fetal 
monitoring is therefore to maximise gestational age at 
birth while minimising the risk of death and sequelae.
Heparin and placenta: biological plausibility
There is in-vitro evidence that heparin improves placental 
perfusion and stimulates neoangiogenesis. Heparin 
exerts its anticoagulant function through the union and 
potentiation of antithrombin, and it also releases tissue 
inhibitory factor to the circulation.2 It also has beneficial 
effects through other routes that do not have to do with 
its anticoagulant effect7: it influences trophoblast growth 
and development, it decreases apoptosis, it acts as an indi-
rect growth factor and it diminishes inflammation via its 
anticomplement effects.8 9
Significant increases in the levels of some proteins that 
play important roles in placental development and angio-
genesis were reported in patients treated with low molec-
ular weight heparin (LMWH), such as leptin, Ang-2, 
vasular endotelial growth factor receptor (VEGFR)-3, 
angiostatin, tissues inhibitors (TIMP-1) and tumoral 
necrosis factor (TNF-α)10–12
In-vitro results indicate that heparin normalises 
matrix metalloproteinases (MMP-9) levels at the level of 
placental microvessels.8 MMP-9 controls trophoblastic 
invasion, and the decrease of its expression in tropho-
blasts as a response to hypoxia reduces invasiveness which 
can impair placenta implantation. LMWH significantly 
increases the levels of both pro-MMP and active forms 
which increases trophoblast invasiveness and promotes 
angiogenesis in vitro.
Heparin also inhibits placental apoptosis by increasing 
cellular protection13 and normalises levels of inflamma-
tory factors (interferon (IFN-γ), transforming growth 
factor (TGF-β1), interleukin (IL) 6, IL-8) that are elevated 
in the microvessels of pregnant women with vascular 
complications.
Much of the available evidence comes from in-vitro 
models; the clinical correlations of these effects described 
in experimental models are poorly characterised.
These data suggest that LMWH has effects beyond 
its antithrombotic action, improving the microvessel 
structure and function of pregnant women with vascular 
obstetric complications by normalising levels of proan-
giogenic and antiapoptotic proteins, cytokines and 
inflammatory factors at the microvessel level. These 
changes facilitate appropriate invasion and angiogen-
esis activity to promote endothelial cell and trophoblast 
survival.
Heparin and placenta: clinical evidence
There are few high-quality clinical studies on the efficacy of 
heparin in gestation. A review14 involving 10 randomised 
trials with 1139 patients concluded that for women at high 
risk of complications secondary to placental insufficiency, 
treatment with heparin was associated with significant 
reductions in perinatal mortality, prematurity before 34 and 
37 weeks and low fetal weight for gestational age. However, 
these studies only include pregnant women at risk, mainly 
with a history of placental insufficiency in a previous preg-
nancy. Another recent meta-analysis15 (including six clinical 
trials) showed that in high-risk pregnant women treated 
primarily with aspirin, the addition of LMWH reduced the 
incidences of PE and low birth weight for gestational age by 
~50%. However, another large individual patient meta-anal-
ysis failed to find any benefit of heparin in women with high-
risk pregnancy.16
Despite the evidence of potential benefit for secondary 
prevention of placental insufficiency and its complica-
tions, there is scant and contradictory evidence about its 
benefit in pregnant women who already have placental 
insufficiency. It would be in this clinical indication, which 
is associated with greater complication risk and need for 
preterm birth, that the necessary number of patients to 
treat may prove to be more beneficial. Four clinical trials 
were performed in women with placental insufficiency 
during gestation, and they employed heterogeneous diag-
nostic criteria and methodological aspects and results. 
Kingdom et al17 and Souza et al18 randomised patients 
with clinical criteria for placental insufficiency who were 
treated with heparin or placebo and did not observe signif-
icant differences in gestational age at birth (35.6 weeks vs 
34.3 weeks and 35.69 weeks vs 33.5 weeks, respectively) or 
perinatal morbidity and mortality. In contrast, Yu et al19 20 
demonstrated significant differences in gestational age at 
birth (37 weeks vs 38 weeks and 36.2 weeks vs 37.1 weeks) 
and fetal birth weight in patients with placental insuffi-
ciency treated with heparin.
study justification
There is good biological evidence on the potential bene-
ficial effects of heparin on the placenta, but the clin-
ical correlation of the effects described in experimental 
models is lacking. In addition, the clinical evidence of 
its benefit to treat gestation already complicated with 
placental insufficiency is weak and contradictory. Heparin 
has the potential to prolong gestation during a clinically 
important period to maximise gestational age at birth to 
reduce mortality and perinatal sequelae.
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Treatment with LMWH at the time of diagnosis of early 
onset IUGR prolongs the latency to severe fetal impair-
ment, increasing the gestational age at delivery of these 
patients.
secondary hypothesis
i. Treatment with LMWH at the time of diagnosis of 
early onset IUGR reduces neonatal morbidity.
ii. Treatment with LMWH at the time of IUGR diagnosis 
improves maternal and placental biochemical, angio-
genic and inflammatory profiles.
iii. Treatment with LMWH at the time of diagnosis of 
early-onset IUGR reduces placental lesions secondary 
to poor placental and fetal perfusion.
objECtIvEs
primary objectives
To demonstrate the effectiveness of LMWH in prolonging 
gestation in pregnancies with early-onset IUGR.
secondary objectives
i. To demonstrate the effectiveness of LMWH in reduc-
ing neonatal morbidity in pregnancies with early-on-
set IUGR.
ii. To demonstrate the effect of LMWH in improving 
proangiogenic and anti-inflammatory maternal and 
placental profiles in pregnancies with early-onset 
IUGR.
iii. To demonstrate the effects of LMWH in reducing 
thrombotic and ischaemic placental lesions.
trIAl dEsIgn
This is a multicentre, triple-blinded, randomised, phase 
III trial with two groups in parallel.
MEtHods
study setting
The study will be conducted within Spanish academic 
hospitals with specialist experience in managing IUGR: 
Hospital Sant Joan de Déu (Barcelona), Hospital Clínic 
(Barcelona) and Hospital Clínico Lozano Blesa (Zara-
goza). The first two hospitals are legally integrated in 
the Center of Maternal Fetal and Neonatal Medicine of 
Barcelona (BCNatal). Each of these hospitals has over 





II. Diagnosis of early onset IUGR according to the Del-
phi classification21 (20–32 weeks at diagnosis) with 
umbilical artery Doppler with absent/reversed dia-
stolic flow; or estimated fetal weight <10th percentile 
plus pulsatility index (PI) of umbilical artery Dop-
pler >95th percentile or estimated fetal weight <10th 
percentile plus mean PI of uterine artery Doppler 
>95th percentile.
III. The weeks for inclusion will be between 20–32 weeks 
of gestation, at the moment of the diagnosis.
Exclusion criteria
I. Abnormal karyotype, structural abnormalities or 
congenital infections.
II. Treatment with LMWH or oral anticoagulants prior 
to inclusion.
III. History of heparin-induced thrombocytopenia.
IV. Active haemorrhage or increased risk of bleeding 
due to haemostatic changes.
V. Severe hepatic or pancreatic dysfunction.
VI. Organic lesions that can bleed (eg, active peptic 
ulcer, haemorrhagic stroke, aneurysm or brain 
tumour).
stop treatment criteria
I. Intolerance or hypersensitivity to bemiparin.
II. Allergic reaction.
III. Clinically relevant bleeding (requiring hospitalisa-
tion).
IV. Requirement of LMWH per clinical indication.
IntErvEntIon
Patients who agree to participate and provide signed 
informed consent will be centrally randomised (via a 
website) through the Clinical Trials Unit (CTU) of Sant 
Joan de Déu Hospital in Barcelona (block randomisation 
of 10) to 3500 IU/0.2 mL/day of subcutaneous (sc) bemi-
parin sc or placebo of the same presentation as the active 
drug, from inclusion to delivery (estimated median of 5–6 
weeks, maximum of 17 weeks).
The treatment will be delivered to the patients weekly 
using the same presentation and labelled with the study 
identification and participant number.
Control vArIAblEs
1. Maternal age at birth; continuous (years).
2. Smoking during gestation; continuous (cigarettes/
day).
3. Maternal weight at the beginning of gestation; con-
tinuous (kg).
4. Maternal height; continuous (cm).
5. Maternal ethnic origin; categorical (Europe, Africa, 
South America, Maghreb, Asia, Others).
6. Parity (number of deliveries >22 weeks); discrete.
7. History of PE22; binary (yes/no).
8. History of gestational hypertension; binary (yes/no).
9. History of IUGR (birth weight below the 10th percen-
tile)23; binary (yes/no).
10. Gestational age at the inclusion in the study; contin-
uous (weeks).
 on 21 N
ovem









pen: first published as 10.1136/bm





4 Mazarico E, et al. BMJ Open 2018;8:e020501. doi:10.1136/bmjopen-2017-020501
Open access 
11. Diastolic blood pressure (DBP) at inclusion; contin-
uous (mm Hg).
12. Systolic blood pressure (SBP) at inclusion; continu-
ous (mm Hg).
13. Mean PI of the uterine arteries at inclusion and be-
fore delivery; continuous (normalised by gestational 
age).24
14. PI of the umbilical artery at inclusion and before de-
livery; continuous (normalised by gestational age).25
15. PI of the middle cerebral artery at inclusion and be-
fore delivery; continuous (normalised by gestational 
age).26
16. PI of the ductus venosus at inclusion and before de-
livery; continuous (normalised by gestational age).27
17. Hypertension in current pregnancy; binary (yes/no).
18. PE in current pregnancy; binary (yes/no).
outCoMEs
primary outcomes
Gestational age at live birth (dated by ultrasound <14 
weeks by measurement of crown rump length; contin-
uous (mm).28
Prolongation of pregnancy: time from inclusion to live 
birth.
secondary outcomes
1. IUGR: birth weight less than the 10th percentile 
for our population23 with PI of the umbilical artery 
during the third trimester (on two separate occasions 
>48 hours) higher than the 95th percentile25; binary 
(yes/no).
2. PE22: DBP ≥90 mm Hg and/or SBP ≥140 in two sep-
arate determinations, >4 hours with proteinuria 
>300 mg/24 hours or other maternal organ dysfunc-
tion/renal insufficiency, liver involvement, neurolog-
ical complications, haematological complications); 
binary (yes/no).
3. Severe PE: PE with blood pressure ≥110/160 mm 
Hg, oliguria (<400 mL/24 hours), neurological symp-
toms, acute pulmonary oedema, persistent epigastric 
pain, hepatic dysfunction, analytical signs of hae-
molysis (lactate dehydrogenase >700 U/L), and/or 
thrombocytopenia (<100 000/mL); binary (yes/no).
4. Preterm birth before 34 weeks of gestation; binary 
(yes/no).
5. Emergent caesarean section for loss of fetal well-be-
ing; binary (yes/no).
6. Birth weight; continuous (g).
7. Neonatal acidosis (arterial pH <7.10+  base excess 
>12 mEq/L); binary (yes/no).
8. Perinatal mortality (from 22 weeks of gestation to 28 
days post partum); binary (yes/no).
9. Days in the neonatal intensive care unit; continuous 
(days).
10. Neonatal morbidity (seizures, intraventricular hae-
morrhage grade III or IV, periventricular leukoma-
lacia, hypoxic–ischaemic encephalopathy, abnormal 
electroencephalogram, necrotising entercholitis, 
acute renal failure (serum creatinine >1.5 mg/dL) 
or heart failure (requiring inotropic agents); binary 
(yes/no).
11. Biomarkers in maternal blood at the time of diag-
nosis and delivery: soluble fms-like tyrosine kinase 1 
(sFlt) and placental growth factor (PlGF); continu-
ous (pg/mL).
12. Biomarkers in umbilical cord blood: TNF-α, IL-6, 
IFN-γ, FGF basic, VEGF and PlGF; continuous.
13. mRNAs in trophoblast: IL-6, IFN-γ, TNF-α, VEGFA, 
VEGFB, FGF2, and RQVEGF Receptor1; continuous.
pArtICIpAnt tIMElInE
Table 1 shows the participant timeline.
sAMplE sIzE
A systematic review (PubMed and ISI Web of Knowledge) 
of clinical trials published in pregnant women suspected 
of placental insufficiency involving heparin treatment 
(both unfractionated and LMWH) only identified four 
studies with good or very good quality (Newcastle-Ottawa 
scale). The meta-analysis of these studies demonstrated 
very high heterogeneity under a fixed-effect model 
(I290.4%) to estimate the difference in gestational age at 
birth between groups. Under a random effects model, the 
mean difference in gestational age at delivery was 1 week 
with an SD of 0.9. Under these assumptions, the sample 
needed to detect a clinically relevant difference (fixed 
at 1 week) at gestational age at delivery with a power of 
95% and an alpha risk of 5% was 22 patients per arm (44 
patients in total). To compensate for possible withdrawals, 
we will require 25 per arm (50 patients).
AlloCAtIon
Using an online service (http://www. randomization. 
com), randomisation sequences will be generated in 
blocks of six subjects to ensure balanced distribution 
within study arms, stratified by participating site. Rando-
misation sequences will be also stratified for <28 and 
≥28 completed weeks and for umbilical artery Doppler 
with present or absent/reverse end diastolic flow. The 
allocation sequence will be internally sequestered by a 
CTU. At the time of the diagnosis and after enrolment, 
recruiting physicians will obtain the allocation group 
from a web-based system. Each treatment pack will 
only be identified by a randomisation code. The treat-
ment allocation will only be revealed to the researchers 
after study completion or when clinically essential. The 
Pharmacy Department of Sant Joan de Déu Hospital 
will provide labelling for all packs and blister sheets, 
ensuring complete blinding to all participants and inves-
tigators including the principal investigator, participating 
research doctors, project managers and others involved 
in the trial. Matching placebo will be identical to the 
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intervention (bemiparin) in such parameters as size, phys-
ical properties and appearance. The Pharmacy Depart-
ment will keep the randomisation code list confidential.
pArtICIpAnt CoMplIAnCE And blIndIng proCEss
Compliance will be assessed by trial teams by counting 
remaining injections at each follow-up visit and inquiring 
about compliance weekly. Participants will be encouraged 
to report any concerns or side effects in a diary for review 
at each trial visit. Blinding success will be assessed before 
delivery by asking the managing doctor about suspicion 
of treatment arm (ie, due to the presence of bruising).
dAtA CollECtIon
Patients will be recruited at the time of diagnosis of 
early onset IUGR, when fetal–placental Doppler study 
is routinely performed to obtain the mean PIs of the 
uterine arteries, umbilical artery, middle cerebral artery 
and ductus venosus. Maternal blood will be collected at 
the time of diagnosis to study angiogenic factors. The 
control variables defined in the previous section will also 
be collected in the first visit. Participant data from this first 
visit and subsequent visits for this study (anonymised) will 
be entered into an electronic case report form (e-CRF) 
hosted on a secure website by each site coordinator. Logic 
and range rules operate in the e-CRF to minimise impu-
tation errors.
Maternal blood, cord blood and placenta will be 
collected at the time of delivery. Perinatal outcomes will 
be collected after delivery.
obtaining and processing of maternal blood samples
We will collect 5 mL maternal blood in tubes without 
anticoagulant. They will be transported to the labora-
tory within 1 hour after extraction, maintaining each 
centre’s safety guidelines for the transport of biological 
material. Blood tubes will be centrifuged at 1500 g for 
15 min. Supernatant (serum) will be aspirated, stored in 
cryophials, properly labelled and kept in a –80°C freezer. 
Levels of PlGF and SFlt-1 (pg/mL) will be determined 
using an Elecsys automated platform by electrochemilu-
minescence (Cobas analyzers, Roche Diagnostics). The 
intra-assay and interassay coefficients of variation are 
<4% and 2.4%–4.6%, respectively.
Collection and processing of cord blood samples
After fetal extraction, umbilical cord venous blood will 
be collected in a 10 mL silicone tube without additives. 
Samples will be transported to the laboratory within 
1 hour of extraction, maintaining our centre’s safety 
guidelines for transport of biological material. Blood 
tubes will be centrifuged at 1500 g for 15 min. Supernatant 
(serum) will be aspirated and stored in properly labelled 
cryophials in an −80°C freezer until analysis in duplicate 
in the LABSCAN 100 Multiplex Analyzer (Luminex) 
(LUMINEX 100 IS software).
Collection and processing of placental tissue samples
After delivery, two placental tissue biopsies will be stored 
in later RNA in aliquots at –80°C until the time of analysis. 
DNA will be extracted from fresh placental tissue with 
Flexigene (Qiagen). Placentas will then be fixed in buff-
ered formalin. After gross examination, routine samples 












  Concealment X
  Revealment X
Assessments
  Sociodemographic data X
  Medical history X
  Follow-up: ultrasound biometries and Doppler 
assessment
X*
  Biomarkers in maternal blood X X
  Ensure compliance X
  Biomarkers in cord blood and placenta X
  Check side effects/adverse events X
  Perinatal outcome X
*According to local protocol (https://medicinafetalbarcelona.org/clinica/images/protocolos/patologia__fetal/cir-peg.pdf).
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will be obtained from each specimen: one transverse 
section of cord, one rolled strip of membranes and three 
blocks from the placental parenchyma. Additional blocks 
will be taken from all macroscopic lesions. Placental 
findings will be reported as described in the Amsterdam 
Consensus.29
Maternal blood, cord blood and placental tissue samples 
will be analysed in the Centro de Investigación Biomédica 
de Aragón (CIBA), Aragon Institute for Health Research (IIS 
Aragón) Zaragoza, Spain.
dAtA MonItorIng And sAfEty
An independent CTU will perform an offline data audit 
every 6 months checking for missing information and 
errors. The same committee will monitor safety issues. 
There may be unexpected adverse reactions associated 
with LMWH. All investigators have a thorough under-
standing of the anticipated adverse events and the appro-
priate reporting process. The investigators will notify the 
Independent CTU of adverse events, and they will report 
to the regulatory authority and ethics committee.
pAtIEnt And publIC InvolvEMEnt
Patients were not involved in any part of the design of the 
study.
stAtIstICAl AnAlysIs
Analysis will be based on originally assigned groups 
(intention-to-treat). However, it is possible that there will 
still be some missing data at the end of the study, so sensi-
tivity analyses will be carried out to confirm the robust-
ness of the results.
The primary objectives will be analysed by linear regres-
sion model for gestational age and time from randomis-
ation to live birth, in which the following covariates are 
considered: gestational age at inclusion (continuous) and 
PE (binary). Stillbirths will be considered as missing data 
will be addressed by multiple imputation methods. Still-
birth cases will be penalised in the analysis by imputing 
them 0 days of prolongation.
The number of patients included (~50) only allows 
adjustment by two variables to maintain power >80%.
Secondary objectives will be analysed by:
I. Univariate analysis:
A. Continuous variables: Student’s t-test (or 
Mann-Whitney U tests for non-normal distribu-
tion, Shapiro-Wilk’s test, p<0.05).
B. Categorical variables: two Pearson's (or Fisher's 
exact test).
III. Multivariate analysis using linear regression (for con-
tinuous dependent variables) or logistic regression 
(for binary variables).
EtHICs And dIssEMInAtIon
The study will be conducted in accordance with the prin-
ciples of Good Clinical Practice. Results will be published 
in peer-reviewed journals and disseminated at interna-
tional conferences.
Patients will be informed that their participation in the 
trial will be treated with the same confidentiality as their 
clinical documentation, but, if necessary, a member of 
the clinical research ethics committee of the centre, an 
inspector appointed by the health authorities or the clin-
ical trial monitor may have access to it. In the data-collec-
tion notebook, the patient will only be identified by her 
study inclusion number.
The trial has been entered in the public registry www. 
clinicaltrial. gov according to Science Law 14/2011, and 
the results will be published in an open access journal.
dIsCussIon
The main limitation is the small sample size. However, 
the results will be very useful for designing larger, future 
trials, and it will provide mechanistic data on biomarkers 
in maternal blood, cord blood and placenta.
Although prolongation of pregnancy is a useful surro-
gate of perinatal health, the study would be largely 
underpowered if we set neonatal mortality/morbidity as 
a primary outcome.
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